Bausch & Lomb Corp (BLCO) financials — revenue, cash, debt and margins

Bausch & Lomb Corp (BLCO) financials — revenue, cash, debt and margins — InspectStocks

Key figures

Trailing twelve months where a flow is involved, latest reported balance where it is not.

Valuation

Market cap: $6.1B
P/E (TTM): —
Price / sales: 1.15
EV / EBITDA: 14.76
Price / book: 0.96

Cash flow

FCF yield: 2.2%
SBC-adjusted FCF yield: -0.4%
SBC impact: 119.0%
Stock compensation (TTM): $163M

Margins & growth

Profit margin: -3.2%
Operating margin: 6.1%
Quarterly revenue (year on year): 9.1%
Quarterly earnings (year on year): —

Balance sheet

Cash & investments: $367M
Debt: $5.1B
Net cash / (debt): -$4.7B

Where the revenue comes from

Device Products is 38% of revenue.

By product or service

Year to Dec 31, 2025 · $5.1B

Device Products38%
$1.9B+6.8% vs. a year earlier
Over the Counter Products36%
$1.8B+6.4% vs. a year earlier
Pharmaceutical Products21%
$1.1B+11.6% vs. a year earlier
Branded and Other Generic Products5%
$243M-13.5% vs. a year earlier
Product and Service Other0.41%
$21M+23.5% vs. a year earlier

By business segment

Year to Dec 31, 2025 · $5.1B

Vision Care57%
$2.9B+6.7% vs. a year earlier
Pharmaceuticals25%
$1.3B+6.2% vs. a year earlier
Surgical18%
$894M+6.0% vs. a year earlier

By region

Year to Dec 31, 2025 · $5B

United States and Puerto Rico51%
$2.5B+5.5% vs. a year earlier
Other Countries15%
$777M+9.1% vs. a year earlier
China7%
$358M0.0% vs. a year earlier
France5%
$246M+8.4% vs. a year earlier
Japan4%
$186M+3.3% vs. a year earlier
Germany3%
$164M+7.9% vs. a year earlier
Russia3%
$148M+23.3% vs. a year earlier
United Kingdom3%
$137M+3.8% vs. a year earlier
Canada3%
$135M+6.3% vs. a year earlier
Italy2%
$102M+12.1% vs. a year earlier
Spain2%
$101M+9.8% vs. a year earlier
Mexico1%
$75M0.0% vs. a year earlier
South Korea1%
$51M+8.5% vs. a year earlier

What it owns and what it owes

Both on one scale, because both are money — the bar that is taller is the one that matters.

Cash and debt

Cash & InvestmentsTotal Debt

Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.

Where the money goes

Cost of RevenueR&D ExpenseSG&A Expense

Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.

The rest of the series

Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each bar sums the four quarters ending there — a full year, brought up to today.

Total Revenue

$5.32BQ2 2026+2.2%

1Y: +8.85%2Y: +18.44%

Everything the company sold, before any costs. Each bar sums the four quarters ending there — a full year, brought up to today.

EBITDA

$734MQ2 2026+13.8%

1Y: +57.85%2Y: +36.18%

Operating profit before depreciation and amortisation — approximated from operating income, because no depreciation tag is reported consistently enough across filers to do better. Treat it as indicative. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit

-$171MQ2 2026+21.9%-3.2% of revenue

1Y: +37.36%2Y: +62.50%

What was left after every cost, including tax. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit margin

-3.2%Q2 2026+23.6%

How much of every dollar of sales the company keeps as profit. A grocer keeps a few cents; a software company can keep half. Each point covers the four quarters ending there — a full year, brought up to today.

Free Cash Flow

$137MQ2 2026+13,600.0%

1Y: +183.03%2Y: +200.00%

Cash left over after running and maintaining the business. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit per share

-$0.49Q2 2026+22.2%

1Y: +37.18%2Y: +62.31%

The same profit, split across every share. If this lags the profit chart above, the company is issuing shares and your slice is getting smaller. Restated onto today’s share count, so stock splits do not show as jumps. Each bar sums the four quarters ending there — a full year, brought up to today.

Shares outstanding

355.23MQ2 2026+0.2%

How many shares the profit is divided across. Rising is dilution; falling is the company buying itself back. Restated onto today’s basis, so splits do not show as jumps. Each point covers the four quarters ending there — a full year, brought up to today.

Price to earnings

86.1xQ4 2022+115.2%

Paid per unit of yearly profit. Periods with a loss, or profits too small for the ratio to mean anything, are left out — the line breaks rather than drawing through them. Each point covers the four quarters ending there — a full year, brought up to today.

About Bausch & Lomb Corp

Ticker: BLCO
SEC classification: Ophthalmic Goods (3851)
Listed on: NYSE
Financial year ends: December 31
Filer size: Large accelerated filer

About this data

Everything above comes from Bausch & Lomb Corp’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.

Not reported by this filer: Cost of Revenue, Gross Profit, R&D Expense, Interest Income, Net Interest Income, Non-interest Income, Non-interest Expense, Deposits, Loans, Short-term Investments, Short-term Borrowings, Borrowings (total), Finance Lease (current), Finance Lease (noncurrent), Dividends paid, Amortization of Intangibles, and Share Repurchases. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.

Key figures

Trailing twelve months where a flow is involved, latest reported balance where it is not.

Valuation

Market cap: $6.1B
P/E (TTM): —
Price / sales: 1.15
EV / EBITDA: 14.76
Price / book: 0.96

Cash flow

FCF yield: 2.2%
SBC-adjusted FCF yield: -0.4%
SBC impact: 119.0%
Stock compensation (TTM): $163M

Margins & growth

Profit margin: -3.2%
Operating margin: 6.1%
Quarterly revenue (year on year): 9.1%
Quarterly earnings (year on year): —

Balance sheet

Cash & investments: $367M
Debt: $5.1B
Net cash / (debt): -$4.7B

Where the revenue comes from

Device Products is 38% of revenue.

By product or service

Year to Dec 31, 2025 · $5.1B

Device Products38%
$1.9B+6.8% vs. a year earlier
Over the Counter Products36%
$1.8B+6.4% vs. a year earlier
Pharmaceutical Products21%
$1.1B+11.6% vs. a year earlier
Branded and Other Generic Products5%
$243M-13.5% vs. a year earlier
Product and Service Other0.41%
$21M+23.5% vs. a year earlier

By business segment

Year to Dec 31, 2025 · $5.1B

Vision Care57%
$2.9B+6.7% vs. a year earlier
Pharmaceuticals25%
$1.3B+6.2% vs. a year earlier
Surgical18%
$894M+6.0% vs. a year earlier

By region

Year to Dec 31, 2025 · $5B

United States and Puerto Rico51%
$2.5B+5.5% vs. a year earlier
Other Countries15%
$777M+9.1% vs. a year earlier
China7%
$358M0.0% vs. a year earlier
France5%
$246M+8.4% vs. a year earlier
Japan4%
$186M+3.3% vs. a year earlier
Germany3%
$164M+7.9% vs. a year earlier
Russia3%
$148M+23.3% vs. a year earlier
United Kingdom3%
$137M+3.8% vs. a year earlier
Canada3%
$135M+6.3% vs. a year earlier
Italy2%
$102M+12.1% vs. a year earlier
Spain2%
$101M+9.8% vs. a year earlier
Mexico1%
$75M0.0% vs. a year earlier
South Korea1%
$51M+8.5% vs. a year earlier

What it owns and what it owes

Both on one scale, because both are money — the bar that is taller is the one that matters.

Cash and debt

Cash & InvestmentsTotal Debt

Where the money goes

Cost of RevenueR&D ExpenseSG&A Expense

Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.

The rest of the series

Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each bar sums the four quarters ending there — a full year, brought up to today.

Total Revenue

$5.32BQ2 2026+2.2%

1Y: +8.85%2Y: +18.44%

Everything the company sold, before any costs. Each bar sums the four quarters ending there — a full year, brought up to today.

EBITDA

$734MQ2 2026+13.8%

1Y: +57.85%2Y: +36.18%

Profit

-$171MQ2 2026+21.9%-3.2% of revenue

1Y: +37.36%2Y: +62.50%

What was left after every cost, including tax. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit margin

-3.2%Q2 2026+23.6%

Free Cash Flow

$137MQ2 2026+13,600.0%

1Y: +183.03%2Y: +200.00%

Cash left over after running and maintaining the business. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit per share

-$0.49Q2 2026+22.2%

1Y: +37.18%2Y: +62.31%

Shares outstanding

355.23MQ2 2026+0.2%

Price to earnings

86.1xQ4 2022+115.2%

About Bausch & Lomb Corp

Ticker: BLCO
SEC classification: Ophthalmic Goods (3851)
Listed on: NYSE
Financial year ends: December 31
Filer size: Large accelerated filer

About this data

Everything above comes from Bausch & Lomb Corp’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.